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IL = interleukin; IPF = idiopathic pulmonary fibrosis; TGF = transforming growth factor; UIP = usual interstitial pneumonia.
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Introduction
An excellent recent review of IPF by Selman et al. [1] out-
lines current concepts regarding pathogenesis and sug-
gests a new hypothesis for the aetiology of this
progressive and usually fatal disease. IPF has recently
been classified in diagnostic pathology terms as usual
interstitial pneumonia (UIP) in order to differentiate it from
other forms of pneumonitis that are associated with differ-
ent pathogeneses and a more favourable prognosis [2].
A great number of IPF/UIP patients show no evidence of
ongoing inflammation, raising questions as to whether IPF
is truly associated with chronic inflammation. Through an
extensive study of the literature, Selman et al. arrived at
the conclusion that there is a lack of definitive evidence
that IPF is a chronic inflammatory disease and suggested
an alternate hypothesis that is consistent with clinical and
morphological features. They proposed that IPF is a disor-
der that involves abnormal wound healing and that
ongoing epithelial damage and/or epithelial cell activation
results in abnormal mesenchymal cell activation, with
derivation of myofibroblasts and excess matrix deposition.
These latter aspects of alteration of mesenchymal cell
phenotype and chronic interaction with epithelium,
through communication by cytokines and matrix, drive the
chronic and progressive nature of IPF, rather than any
inflammatory component. These concepts are interesting
and fit more with clinical findings than the concept of
chronic inflammatory cell involvement. Moreover, the lack
of reliance on inflammation is in accord with the lack of
resolution of the progressive process on treatment with
potent anti-inflammatory drugs.
Current concepts of inflammation and
fibrosis
After lung injury, acute inflammation and tissue repair
mechanisms are engaged to halt the injurious stimulus,
remove infectious organisms if present, and initiate immedi-
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ate repair to crucial membranes that function to provide
gas exchange for survival. This usually results in the even-
tual return of the organ to normal function. However, in
chronic tissue injury, with repeat episodes of inflammation,
many of the control mechanisms involved in this otherwise
well orchestrated process are bypassed. Continued repair
results in disorder of the tissue, distorted matrix deposition,
mesenchymal cell proliferation and alteration to normal lung
structure, with compromised gas exchange function; this
overall process is known as fibrosis. In cases in which the
initiating event is known, such as with postradiation fibrosis
or with asbestos- or silica-induced injury, the pathogenesis
appears to follow the inflammatory response. In the majority
of cases of pulmonary fibrosis, however, no known initiating
event is recognized and IPF is diagnosed [3].
During the past decade a number of investigators con-
ducted mechanistic studies aimed at defining the patho-
genic mechanisms that are involved in IPF. It has long
been believed that IPF is a process of chronic repair that
results from persistent inflammation with attendant activa-
tion of inflammatory cells and local presence of mediators
(cytokines and growth factors) that are capable of activat-
ing mesenchymal cells, with enhanced matrix production
and deposition. Inflammation is usually identified on the
basis of morphology and demonstration of accumulation
of inflammatory cells, such as neutrophils and/or
eosinophils and mast cells in biopsy material. The mor-
phology is mostly descriptive, and there are few specific
protein measurements in either lumen washes or in lung
tissue regarding the mediators that are involved in the
process. Moreover, single snapshots of chronic processes
cannot reveal much about a disease that has such a
lengthy period (years) and for which there is no known
natural history. Thus, we are limited to information gleaned
from experimental animal models to help us determine the
temporal, cellular and molecular mechanisms of pathogen-
esis, and develop therapeutic interventions.
Selman et al. [1] suggested that the natural history of the
disease has more to do with intrinsic aberrant wound
healing than with inflammation, and described pathways of
interaction between injured alveolar epithelium and
parenchymal fibroblasts that result in altered mesenchymal
cell phenotype and fibrogenesis (fibroblast proliferation,
myofibroblast differentiation and matrix synthesis). In the
first instance their argument is compelling and makes
sense, given the data obtained in human samples along
with those recently obtained in experimental models.
Moreover, there are many examples in embryonic develop-
ment of tissue remodelling through release of cytokines
and growth factors, without attendant or preceding inflam-
mation. It is thus reasonable to assume that such activities
may be recapitulated in at least some aspects of chronic
tissue repair. Communication between the epithelium and
mesenchymal cells is crucial for development of the
normal lung, and central to organ development is tissue
remodelling [4,5].
Is inflammation required for fibrogenesis?
Crucial to the suggested interaction of epithelium and
mesenchyme is transforming growth factor (TGF)-β. This
factor is involved in normal alveolar development and in
regulation of repair processes, in addition to its broad
activities in regulating the immune response [6]. Most
important is the demonstration that TGF-β is an integral
component of fibrotic tissue in IPF [7,8], with a known role
in causing the differentiation of myofibroblasts (a critical
element in tissue repair and fibrosis) [9].
Importantly, Munger et al. [10] recently showed that activa-
tion of latent TGF-β through expression of the integrin αvβ6
can generate fibrogenic conditions. This could occur either
in the presence or absence of ongoing inflammation, and
thus could progress to fibrosis in an independent manner.
We conducted studies with adenovirus vectors that
express individual cytokine and growth factor genes
administered to the lung epithelium. Those studies demon-
strate, at least in the animal model, that remodelling can
occur subsequent to acute inflammation (as is seen with
over-expression with IL-1β) [11] or independent of inflam-
Table 1
Transfer of cytokines by adenovirus vector to the rodent lung
Cytokine Degree of inflammation TGF-β Myofibroblasts Fibrosis
IL-1β Acute +++; alveolar destruction 400 pg/ml +++ ++++
TNF-α Acute +++ 150 pg/ml + +
GM-CSF Acute ++ 600 pg/ml ++ ++
TGF-β1 Minimal to absent >50 ng/ml ++++ ++++
Degree of inflammation ranges from 0 to ++++, with 0 representing no detectable inflammation by morphologic examination to ++++ where there
is extensive inflammatory cell accumulation throughout the parenchyma and lumen of the lung. Similar ranges are used for myofibroblast presence
and extent of fibrosis. GM-CSF = granulocyte/macrophage colony-stimulating factor; IL = interleukin; TGF = transforming growth factor; TNF =
tumour necrosis factor.
Page 2 of 3
(page number not for citation purposes)
mation (as seen with over-expression of active TGF-β1)
[12]. Over-expression of other factors that have been
identified as being profibrogenic exhibit acute inflamma-
tion with minimal remodelling, as with tumour necrosis
factor-α [13], or both acute and chronic inflammation with
moderate remodelling, as with granulocyte/macrophage
colony-stimulating factor [14]. The common theme is the
generation of active TGF-β, and the extent of fibrosis and
myofibroblast induction appears related to the level of
TGF-β present (Table 1).
Sheppard [15] commented that the inflammation induced
by transient expression of IL-1β and associated with fibro-
sis is temporal, with fibrogenesis occurring after the tran-
sient expression of IL-1β had subsided and the induced
levels of TGF-β were prolonged. This suggests that inflam-
mation may precede the onset of fibrosis by setting in
motion a series of cell activations and/or matrix alterations
that result in prolonged mesenchymal and epithelial inter-
action, probably through TGF-β. Thus, the chronic
process of fibrosis may be separated from the acute
process of inflammation, and inflammation appears neces-
sary but not sufficient to explain the pathophysiology of
fibrosis. This would appear more consistent with the sus-
pected natural history of IPF.
A further issue, which supports both the need for and
absence of inflammation in fibrosis, needs to be consid-
ered. This is the recently described expression of CD40
(the receptor for CD40 ligand) by fibroblasts and other
mesenchymal cells [16]; the CD40 system is normally
associated with induction of the immune response. Phipps
[16] summarized the data reported when fibroblast CD40
ligation occurs, resulting in upregulation of cyclo-oxyge-
nase-2 and various cytokines that are characteristic of a T-
helper-2-like environment [16], which is known to be
preferential to a fibrogenic response [17,18]. In addition to
T cells, the platelet is a very rich source of CD40 ligand,
and as such mesenchymal cell activation and stimulation
may occur through platelet degranulation or immune acti-
vation, processes that can occur in the absence of acute
inflammation [19].
Conclusion
In summary, the concept of inflammation-independent fibro-
sis, put forth by Selman et al. [1], is supported by clinical,
developmental biology and immune regulation data, and
gene transfer studies in animals. Similar studies also
support the concept of fibrogenesis resulting from acute
and chronic inflammation, however. In the absence of
knowledge regarding the natural history of IPF, our best
guess is that IPF is more likely to be a syndrome rather than
one specific disease, and that the end stage of fibrosis,
which may be independent from inflammation, can develop
through multiple aetiologies. Studies with drugs that block
pulmonary fibrosis in humans may clarify the multiple path-
ways to pathogenesis, and demonstrate the validity of
several hypotheses for the mechanism of fibrogenesis.
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